UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 78 filers reported holding UROGEN PHARMA LTD in Q1 2020. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $3,974,000 | -86.0% | 222,776 | -73.8% | 0.97% | -78.4% |
| Q4 2019 | $28,347,000 | +35.6% | 849,478 | -3.2% | 4.49% | +47.2% |
| Q3 2019 | $20,902,000 | -42.6% | 877,120 | -13.5% | 3.05% | +14.4% |
| Q2 2019 | $36,446,000 | -0.0% | 1,014,078 | +2.8% | 2.67% | +16.4% |
| Q1 2019 | $36,455,000 | +83.4% | 986,878 | +113.8% | 2.29% | +72.0% |
| Q4 2018 | $19,880,000 | +26.8% | 461,678 | +39.1% | 1.33% | +83.7% |
| Q3 2018 | $15,676,000 | -5.1% | 331,900 | 0.0% | 0.72% | +31.1% |
| Q2 2018 | $16,515,000 | -11.8% | 331,900 | -11.9% | 0.55% | -13.5% |
| Q1 2018 | $18,724,000 | +25.8% | 376,823 | -5.8% | 0.64% | +29.9% |
| Q4 2017 | $14,880,000 | +15.1% | 399,900 | -2.5% | 0.49% | +34.1% |
| Q3 2017 | $12,923,000 | +68.2% | 410,000 | -3.6% | 0.37% | +51.0% |
| Q2 2017 | $7,681,000 | – | 425,300 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 1,111,050 | $9,099,000 | 4.23% |
| GREAT POINT PARTNERS LLC | 873,424 | $7,153,000 | 1.72% |
| Wildcat Capital Management, LLC | 533,139 | $4,366,000 | 1.45% |
| Opaleye Management Inc. | 238,670 | $1,955,000 | 0.88% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,949,489 | $24,156,000 | 0.44% |
| Annandale Capital, LLC | 84,331 | $691,000 | 0.27% |
| Yahav Achim Ve Achayot - Provident Funds Management Co Ltd. | 25,330 | $206,000 | 0.18% |
| RTW INVESTMENTS, LP | 857,464 | $7,023,000 | 0.18% |
| Harel Insurance Investments & Financial Services Ltd. | 1,025,611 | $8,400,000 | 0.18% |
| BENDER ROBERT & ASSOCIATES | 41,131 | $337,000 | 0.13% |